Rozanolixizumab not checked
UCB Biopharma SRL · UCB7665
FollowEvery change as it happens, and a Monday email
Trials
5 active
22 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “* Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive pre-specified doses of rozanolixizumab.”In the company’s words, NCT05063162 on ClinicalTrials.gov
- Tested for
- Ocular Myasthenia Gravis (2 trials), Myasthenia Gravis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), Generalized Myasthenia Gravis
- Main trialPhase 4
- “The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.”In the company’s words, NCT07246564 on ClinicalTrials.gov
- Other names
- UCB7665 · RLZ
Other drugs for Ocular Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- TelitaciceptVor Biopharma · Phase 3
Coming up5
- 6 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 5 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 15 Oct 2027Phase 4 trial completes · ClinicalTrials.gov
- 1 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 17 Mar 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials22
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 15 Oct 2027 | Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | |
| Phase 3Active, not recruiting | 6 May 2027 | A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD) | |
| Phase 3Active, not recruiting | 5 Oct 2027 | An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | |
| Phase 3Recruiting | 1 Dec 2028 | A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | |
| Phase 3Recruiting | 17 Mar 2031 | A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | |
| Phase 3Completed | 31 Aug 2021 | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | |
| Phase 3Completed | 1 Sep 2021 | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | |
| Phase 3Terminated | 21 Mar 2022 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) | |
| Phase 3Terminated | 25 Apr 2022 | A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) | |
| Phase 3Terminated | 21 Dec 2022 | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) | |
| Phase 3Completed | 25 Jan 2024 | A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis | |
| Phase 3Completed | 23 Apr 2024 | A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) | |
| Phase 2/3Completed | 5 Oct 2026 | A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | |
| Phase 2Completed | 31 May 2018 | Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | |
| Phase 2Completed | 4 Feb 2019 | Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia | |
| Phase 2Completed | 31 Mar 2021 | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |
| Phase 2Completed | 10 Nov 2021 | A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |
| Phase 2Terminated | 8 Mar 2024 | A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | |
| Phase 2Completed | 28 May 2024 | A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome | |
| Phase 1Completed | 28 Apr 2020 | A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants | |
| Phase 1Completed | 11 Apr 2022 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants | |
| Phase 1Completed | 12 May 2025 | A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026